BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22257793)

  • 1. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
    Huang FY; Mei WL; Li YN; Tan GH; Dai HF; Guo JL; Wang H; Huang YH; Zhao HG; Zhou SL; Li L; Lin YY
    Eur J Cancer; 2012 Sep; 48(14):2260-9. PubMed ID: 22257793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
    Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
    Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochalasin D, a tropical fungal metabolite, inhibits CT26 tumor growth and angiogenesis.
    Huang FY; Li YN; Mei WL; Dai HF; Zhou P; Tan GH
    Asian Pac J Trop Med; 2012 Mar; 5(3):169-74. PubMed ID: 22305779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
    Stover TC; Sharma A; Robertson GP; Kester M
    Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice.
    Banciu M; Schiffelers RM; Fens MH; Metselaar JM; Storm G
    J Control Release; 2006 Jun; 113(1):1-8. PubMed ID: 16707187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III.
    Park YS; Hakomori S; Kawa S; Ruan F; Igarashi Y
    Cancer Res; 1994 Apr; 54(8):2213-7. PubMed ID: 8174128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
    Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
    Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway invitro and inhibits tumor growth invivo.
    Xu YZ; Zheng RL; Zhou Y; Peng F; Lin HJ; Bu Q; Mao YQ; Yu LT; Yang L; Yang SY; Zhao YL
    Cancer Lett; 2011 Dec; 313(1):44-53. PubMed ID: 21944661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of polypeptides in bee venom on growth inhibition and apoptosis induction of the human hepatoma cell line SMMC-7721 in-vitro and Balb/c nude mice in-vivo.
    Hu H; Chen D; Li Y; Zhang X
    J Pharm Pharmacol; 2006 Jan; 58(1):83-9. PubMed ID: 16393467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
    Yang C; Liu HZ; Lu WD; Fu ZX
    Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
    Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
    J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.